Early Detection of Cognitive Impairment Using Time–Frequency Analysis of Fine Motor Accelerometry
摘要
Early detection of cognitive decline is essential for timely diagnosis and treatment. This study aimed to evaluate whether upper-limb movement dynamics derived from wrist-mounted inertial sensors during a fine motor task can accurately differentiate among healthy aging, mild cognitive impairment (MCI), and dementia (DEM).
MethodsThe study recruited young and older participants. Cognitive status was established through clinical evaluation together with concordance across three standardized neurocognitive assessments (MMSE, MoCA, and NEUROPSI). Upper-limb dynamics during the Grooved Pegboard Test (GPT) were recorded using a wrist-mounted triaxial BioHarness accelerometer. Time- and frequency-domain features were extracted from the accelerometry signals, and uncorrelated linear discriminant analysis (ULDA) was applied for supervised dimensionality reduction. Classification performance was evaluated using support vector machine (SVM), random forest (RF), and k-nearest neighbors (KNN) classifiers using accuracy and area under the receiver operating characteristic curve (AUC-ROC).
ResultsThe study included 109 participants distributed into four groups: 30 young healthy subjects (YNG), 22 cognitively intact older adults (CIO), 27 participants with MCI, and 30 with DEM. Prior to dimensionality reduction, the SVM classifier achieved the strongest performance, reaching a macro accuracy of 0.88 ± 0.013, demonstrating meaningful discrimination using the original feature representation. ULDA-based projection further improved class separability across all evaluated models. RF + ULDA and SVM + ULDA achieved macro accuracies of 0.97, whereas KNN + ULDA achieved 0.94.
ConclusionFine motor dynamics measured during the GPT contain discriminative information associated with progressive cognitive decline and may support objective, wearable-sensor-based cognitive screening.
Trial registrationThe Local Ethics Committee of the General Hospital of Mexico approved the study, “Dr. Eduardo Liceaga” (protocol code DI/23/110-B/03/12).